Mast Cells Are a Marked Source for Complement C3 Products That Associate with Increased CD11b-Positive Cells in Keratinocyte Skin Carcinomas

By using immunohistochemistry and antibodies that identify complement C3c (in C3 and C3b) or CD11b receptor, we report that the proportion C3c + mast cells and the number of CD11b + cells are increased in basal cell carcinoma (BCC). Instead, only CD11b + cells are increased in squamous cell carcinom...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2019-02, Vol.37 (2), p.73-84
Main Authors: Rahkola, Dina, Laitala, Joel, Siiskonen, Hanna, Pelkonen, Jukka, Harvima, Ilkka T.
Format: Article
Language:English
Subjects:
Actinic keratosis
Basal cell carcinoma
CD11b
Mast cell
Psoriasis
Squamous cell carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:By using immunohistochemistry and antibodies that identify complement C3c (in C3 and C3b) or CD11b receptor, we report that the proportion C3c + mast cells and the number of CD11b + cells are increased in basal cell carcinoma (BCC). Instead, only CD11b + cells are increased in squamous cell carcinoma/Bowen's disease, and only slightly so in actinic keratosis. Only C3c + mast cells are increased in psoriasis. Furthermore, C3c + mast cells correlated positively with CD11b + cells, and iC3b immunoreactivity was detected around tryptase + mast cells. Therefore, mast cells may convey immunoregulatory signals through C3, C3b, and iC3b to CD11b + cells, especially in BCC.
ISSN:0735-7907
1532-4192
DOI:10.1080/07357907.2019.1565765